Generic drugmaker Aurobindo Pharma USA plans to establish a new research and development facility in Durham and create 275 jobs by the end of 2020.
The Dayton, N.J.-based company, a division of the Indian drugmaker Aurobindo Pharma, plans to invest $31.7 million building a new headquarters that will focus on developing specialty pharmaceuticals.
Aurobindo is currently in negotiations to buy and renovate an existing manufacturing facility in Durham, said Ted Connor, vice president of economic development and community sustainability for the Greater Durham Chamber of Commerce.
The company chose Durham over Dayton.
Aurobindo now employs 14 people in Raleigh and 15,500 worldwide. The publicly-traded company makes semi-synthetic penicillins as well as therapeutics for neurosciences, cardiovascular, anti-retrovirals, anti-diabetics and gastroenterology.
The annual payroll for the 275 new jobs is expected to be $17.1 million, or an average of about $62,000 per worker. The new jobs will include researchers, analytical chemists, production operators and quality control specialists.
Gov. Pat McCrory’s office announced the expansion Tuesday. Aurobindo is eligible to receive up to $3.8 million in state incentives if it meets investment and hiring milestones.
The city of Durham and Durham County also have approved $400,000 in incentives for Aurobindo.